Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.

British journal of haematology - 1 Feb 2011

Besses Carlos, Alvarez-Larrán Alberto, Martínez-Avilés Luz, Mojal Sergi, Longarón Raquel, Salar Antonio, Florensa Lourdes, Serrano Sergi, Bellosillo Beatriz

Abstract excerpt

The modulation of JAK2 V617F allele burden dynamics was prospectively analysed in 47 patients (26 polycythaemia vera [PV] and 21 essential thrombocythaemia [ET]) treated with first-line hydroxyurea (HU) and compared with the JAK2 V617F dynamics of a control group of 45 PV and ET patients. A partial molecular response (PMR), according to European Leukaemia Net criteria, was observed in 27/47 (57%) patients. Median...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Genetic Load

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Nucleic Acid Synthesis Inhibitors

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Treatment Outcome

Source

Identifiers

PMID: 21219298
DOI: 10.1111/j.1365-2141.2010.08467.x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.PMID 21219298Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

The treatment of polycythaemia vera: an update in the JAK2 era.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.Semantic proximity Read ↗

Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.Semantic proximity Read ↗

JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.Semantic proximity Read ↗

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.Semantic proximity Read ↗

Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.